Kineta Updates Kva12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study at Society for Immunotherapy of Cancer (2024)
- Latest
- Detail
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
19:15
Airbus says Spain will order 25 more European fighter jets.
19:14
A knife attack occurred at an elementary school in the capital of Croatia, resulting in one death and six injuries.
19:11
Novo-Nordisk A/S's Pre-Market Trading decline narrowed to 20%, having previously dropped nearly 30%, marking the largest single-day decline on record, due to the disappointing trial results of their weight loss drug CagriSema.
NVO-2.38%